JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Recent Progress in UV Spectroscopic and Chromatographic Methods for the Determination of Budesonide in Bulk and Formulations

Bhavya KB*[1], Chethan K S[2], Divya Shree MP[2], Sachin V[2]

[1] *Assistant Professor, Department of Pharmaceutical Analysis, Bharathi College of Pharmacy, Bharathinagara, Mandya, Karnataka, India*
[2] *UG Scholar, Department of Pharmaceutical Analysis, Bharathi College of Pharmacy, Bharathinagara, Mandya, Karnataka, India*

Publication history: Received on 26th June 2025; Revised on 3rd Aug 2025; Accepted on 10th August 2025

Article DOI: 10.69613/nzek4452

Abstract: Budesonide, a potent synthetic corticosteroid with good topical efficacy and limited systemic bioavailability, has established its therapeutic potential in managing asthma, inflammatory bowel disease, and allergic rhinitis. The pharmaceutical analysis of budesonide requires precise, accurate, and validated analytical methods for quality control and research applications. UV spectrophotometry emerges as a prominent analytical technique for budesonide quantification, offering advantages of simplicity, cost-effectiveness, and reliability. The absorption maximum of budesonide at 246 nm provides a suitable wavelength for analysis, with a linearity in the concentration range of 1.4-25 µg/mL. Validation parameters including accuracy, precision, and specificity confirm the method's robustness, with recovery rates of 99-100% and minimal standard deviation. Chromatographic methods, particularly RP-HPLC, complement spectrophotometric analysis by offering enhanced selectivity and sensitivity. Notable developments include stability-indicating methods capable of separating degradation products and specialized techniques for analyzing complex formulations. Recent innovations focus on green analytical approaches and advanced applications in novel drug delivery systems, such as layer-by-layer polymeric nanoparticles. The analytical methodologies show significant potential in quality control laboratories and research settings, supporting both routine analysis and specialized pharmaceutical development applications.

Keywords: Budesonide; UV spectrophotometry; Method validation; Pharmaceutical analysis; Corticosteroids

1. Introduction

Budesonide is a synthetic corticosteroid and has unique molecular design that optimizes local anti-inflammatory effects while minimizing systemic exposure [1]. The compound, chemically designated as (RS)-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde, has emerged as a cornerstone therapy in various inflammatory conditions [2].



Figure 1. Structure of Budesonide

The clinical applications of budesonide span multiple therapeutic areas, with particularly significant impact in respiratory medicine and gastroenterology. In respiratory medicine, budesonide serves as a prophylactic therapy in asthma management, while its role in allergic rhinitis has been established through various formulations including nasal sprays [3]. The compound's therapeutic versatility extends to inflammatory bowel disease (IBD), where controlled-release formulations target specific gastrointestinal segments [4].

* Corresponding author: Bhavya KB

Budesonide's therapeutic success stems from its sophisticated pharmacological profile. As a second-generation glucocorticoid, it exhibits remarkably high affinity for corticosteroid receptors, demonstrating a superior ratio of topical to systemic anti-inflammatory activity [5]. The compound's mechanism of action involves modulation of pro-inflammatory cytokine release and regulation of inflammatory mediators, contributing to its potent anti-inflammatory effects [6]. The development of diverse pharmaceutical formulations has enhanced budesonide's therapeutic utility, particularly through specialized delivery systems and controlled-release mechanisms.

Advanced delivery systems such as dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizer solutions have been developed to optimize pulmonary drug delivery [7]. These formulations require precise analytical methods to ensure accurate dose delivery and product quality. The particle size distribution and aerodynamic properties of these formulations play crucial roles in determining their therapeutic efficacy.

Novel formulation methods include pH-dependent release systems, particularly for IBD treatment, where targeted delivery to specific gastrointestinal regions is crucial [8]. These formulations incorporate sophisticated coating technologies and matrix systems to achieve desired release profiles. The development of such systems necessitates advanced analytical techniques for characterization and quality control. The analysis of budesonide presents unique challenges due to its complex formulation matrices requiring selective analytical methods. Stability considerations across various environmental conditions necessitate robust analytical approaches. The need for high sensitivity in low-dose formulations demands sophisticated instrumentation and methodology. Requirements for stability-indicating methods capable of detecting degradation products further complicate the analytical landscape [9].

Contemporary analytical methods for budesonide include various techniques, with UV spectrophotometry and high-performance liquid chromatography (HPLC) being predominant. These methods must comply with regulatory requirements while providing accurate, precise, and reproducible results [10]. The development of validated analytical methods serves quality control during manufacturing, stability testing and shelf-life determination, formulation development and optimization, clinical pharmacokinetic studies, and research and development applications.

Analytical method development for budesonide must align with current regulatory guidelines, including International Conference on Harmonisation (ICH) requirements for method validation. Pharmacopoeial standards and specifications guide method development, while Good Manufacturing Practice (GMP) requirements ensure consistent quality. Regulatory authority guidelines for specific dosage forms provide additional requirements for analytical method development and validation [11].

2. Analytical Methods for Determination of Budesonide

2.1. UV Spectrophotometric Methods

UV spectrophotometry serves as a fundamental analytical technique for budesonide quantification, offering advantages in terms of simplicity and cost-effectiveness. The method exploits budesonide's characteristic absorption maximum at 246 nm, arising from its conjugated ketone structure [12].

2.2. Method Development

The development of UV spectrophotometric methods involves careful consideration of several analytical parameters. The selection of appropriate solvents proves crucial, with methanol emerging as a preferred choice due to its ability to maintain molecular stability while providing optimal absorption characteristics. The linear concentration range typically extends from 1.4 to 25 μg/mL, offering suitable sensitivity for pharmaceutical analysis [13].

2.3. Validation

Method validation consists of multiple parameters essential for establishing analytical reliability. Linearity studies demonstrate correlation coefficients exceeding 0.999, indicating excellent concentration-response relationships. Precision studies reveal relative standard deviations below 2%, while accuracy assessments show recovery rates between 99-100%. The limit of detection (LOD) reaches 0.01 μg/mL, with a limit of quantification (LOQ) of 1.4 μg/mL [14].

2.4. Chromatographic Methods

HPLC methods for budesonide analysis have evolved significantly, incorporating various detection systems and separation mechanisms. Reversed-phase HPLC emerges as the predominant technique, utilizing C18 columns and carefully optimized mobile phases [15].

Table 1. Comparison of Analytical Methods for Budesonide Determination [14, 16]

Analytical Method	LOD (µg/mL)	LOQ (µg/mL)	Linear Range (µg/mL)	Recovery (%)	Ref.
RP-HPLC-UV	0.05	0.15	0.5-50	99.0-100.5	[14]
LC-MS/MS	0.001	0.005	0.01-10	98.8-101.0	[15]
UPLC-MS	0.02	0.08	0.2-30	99.2-100.8	[16]

2.4.1. Mobile Phase Optimization

The selection of mobile phase composition significantly influences separation efficiency. Acetonitrile-water systems, typically in ratios of 80:20 v/v, provide optimal resolution while maintaining peak symmetry. The incorporation of buffer systems, when necessary, helps maintain consistent pH conditions and improve peak shapes [16].

2.4.2. Detection Systems

Various detection methods serve different analytical requirements:

- Photodiode Array Detection (PDA): Offers spectral analysis capabilities and enhanced selectivity
- UV Detection: Provides robust quantification at 244-247 nm
- Mass Spectrometer: Enables structural characterization and enhanced sensitivity for complex matrices [17]

2.5. Stability-Indicating Methods

2.5.1. Forced Degradation Studies

Comprehensive stability assessment involves subjecting budesonide to various stress conditions:

- Acid hydrolysis: Minimal degradation observed
- Base hydrolysis: Significant degradation with identifiable products
- Oxidative stress: Moderate degradation under peroxide exposure
- Thermal degradation: Variable stability depending on temperature conditions
- Photolytic degradation: Light sensitivity requiring protective measures [18, 19]

Table 2. Quality Control Parameters for Different Budesonide Formulations [8, 13, 19]

Formulation Type	Test Parameters	Acceptance Criteria	Analytical Method	Ref.
DPI	Aerodynamic Particle Size	1-5 µm	Cascade Impaction	[8]
Nasal Spray	Spray Pattern	As per specifications	HPLC	[13]
Oral Suspension	Content Uniformity	90-110%	HPLC-UV	[19]

2.5.2. Degradation Products

The separation and characterization of degradation products utilize advanced analytical techniques. HPLC-MS/MS methods enable structural elucidation of degradants, while maintaining separation from the parent compound. The identification of degradation pathways aids in establishing appropriate storage conditions and shelf-life determination [21, 21].



Figure 2. Method Development and Validation

3. Validation Methods

3.1. Method Validation Parameters

3.1.1. Specificity and Selectivity

Method specificity ensures accurate quantification of budesonide in the presence of excipients, degradation products, and potential interferents. Selectivity studies demonstrate the ability to distinguish between closely related compounds, particularly important in complex formulation matrices [22].

Table 3. Chromatographic Method Validation Parameters [23, 24]

Parameter	Acceptance Criteria	Achieved Results	Reference Method
Precision (%RSD)	≤ 2.0%	0.8-1.5%	[23]
Accuracy	98.0-102.0%	99.0-101.0%	[24]
Method Robustness	%RSD ≤ 2.0%	Complies	[25]

3.1.2. Precision

Precision evaluation encompasses multiple levels of investigation. Repeatability studies examine intra-day variation under identical operating conditions. Intermediate precision assessment considers variations in analysts, instruments, and environmental conditions. Reproducibility studies extend to inter-laboratory comparisons, establishing method robustness across different facilities [23].

3.1.3. Accuracy

Recovery studies validate method accuracy across the analytical range. Standard addition methods verify the absence of matrix effects, while systematic error evaluation ensures method reliability. Multiple concentration levels, typically spanning 80-120% of the target concentration, provide comprehensive accuracy assessment [24].

3.2. Applications in Pharmaceutical Analysis

3.2.1. Quality Control

Validated analytical methods support routine quality control operations in pharmaceutical manufacturing. Raw material testing ensures incoming material quality, while in-process controls monitor manufacturing consistency. Finished product analysis confirms compliance with specifications, supporting batch release decisions [25].



Figure 3. Analytical Quality Control

3.2.2. Assessment of Stability

Long-term stability studies utilize validated methods to monitor product quality throughout the shelf life. Real-time stability data guide storage recommendations and expiration dating. Accelerated stability studies predict potential degradation patterns and identify critical quality attributes [26].

3.2.3. Formulation Development

Analytical method support extends throughout the formulation development process. Pre-formulation studies characterize drug-excipient compatibility, while optimization studies evaluate formulation parameters. Scale-up studies ensure consistent product quality across manufacturing scales [27].

Table 4. Storage Stability Studies of Budesonide Formulations [26, 27]

Storage Condition	Duration	Temperature (°C)	Relative Humidity (%)	Stability Indicators
Long-term	24 months	25 ± 2	60 ± 5	As per ICH Q1A(R2)
Accelerated	6 months	40 ± 2	75 ± 5	As per ICH Q1A(R2)

3.2.4. Bioanalytical Methods

Specialized analytical methods support pharmacokinetic and bioequivalence studies. Plasma analysis requires enhanced sensitivity and selective extraction procedures. Method validation considers matrix effects and stability in biological fluids [28].

3.2.5. Characterization of formulations

Advanced delivery systems demand sophisticated analytical approaches. Controlled release formulations require dissolution profile analysis and release kinetics evaluation.

Table 5. Characteristics of Various Budesonide Formulation Types and Their Analytical Considerations

Formulation Type	Delivery System	Quality Attributes	Analytical Challenges	Special Considerations
Inhalation Products	Dry Powder Inhaler	Particle Size Distribution, Flow Properties	Aerodynamic Assessment	Sample Collection Method [7, 8]
	Metered Dose Inhaler	Dose Uniformity, Spray Pattern	Propellant Interference	Specialized Extraction Procedures [14]
	Nebulizer Solution	Content Uniformity, Sterility	Stability in Solution	Aseptic Analysis Requirements [16]
Oral Formulations	Enteric Coated Tablets	Dissolution Profile, Coating Integrity	pH-Dependent Release	Dissolution Method Development [4]
	Extended Release Capsules	Release Kinetics, Content	Matrix Effect	Stability During Analysis [2]
Nasal Preparations	Aqueous Spray	Spray Pattern, Droplet Size	Device Performance	Environmental Controls [3]
	Powder Spray	Particle Properties, Moisture	Sample Preparation	Humidity Effect Assessment [15]

Particle size analysis supports inhalation product development, while surface characterization aids nanoformulation optimization [29]. Recent developments in budesonide delivery systems, particularly nanoformulations, necessitate specialized analytical approaches. Layer-by-layer polymeric nanoparticles require sophisticated analytical methods for characterization and drug loading assessment [20].

3.2.6. Green Analytical Methods

Contemporary analytical method development emphasizes environmental sustainability. Recent advances incorporate green chemistry principles, utilizing reduced organic solvent consumption and environmentally friendly mobile phases. These methods maintain analytical performance while minimizing environmental impact through optimized separation conditions and reduced waste generation [21].

3.3. Regulatory Compliance

3.3.1. Method Transfer

Analytical method transfer ensures consistent performance across different laboratories. Transfer protocols evaluate critical method parameters and establish acceptance criteria. Statistical analysis confirms method equivalence between sending and receiving laboratories [30].

3.3.2. Documentation

Comprehensive documentation supports regulatory compliance. Method validation protocols detail experimental designs and acceptance criteria. Validation reports present data analysis and conclusions, while standard operating procedures guide routine method execution [31].

4. Recent Trends

4.1. Automation and High-Throughput Analysis

Modern analytical laboratories increasingly implement automated systems for budesonide analysis. Integration of robotic sample preparation, automated injection systems, and data processing enhances analytical throughput while maintaining precision. Machine learning algorithms assist in method optimization and data interpretation, reducing manual intervention and improving efficiency [32].

4.2. Sophisticated Detection Systems

Novel detection technologies enhance analytical capabilities for budesonide determination. High-resolution mass spectrometry enables detailed structural characterization and improved sensitivity. Ion mobility spectrometry provides additional separation dimensions, particularly valuable for complex formulation analysis [33].

Table 6. Advanced Analytical Techniques for Budesonide Analysis [32, 33]

Technique	Application	Detection Limit	Advantages	Ref.
HR-LC-MS	Structure Elucidation	0.0005 μg/mL	High Specificity	[32]
Ion Mobility-MS	Impurity Profiling	0.001 μg/mL	Enhanced Separation	[33]

4.3. Quality by Design in Method Development

4.3.1. Systematic Approach

Implementation of Quality by Design (QbD) principles in analytical method development ensures robust and reliable procedures. Statistical experimental design identifies critical method parameters and their interactions. Design space development provides operational flexibility while maintaining method performance [34].

Table 7. Modern Analytical Approaches for Different Budesonide Sample Matrices and Applications

Sample Matrix	Analytical Technique	Method Characteristics	Validation	Application
Biological Fluids	LC-MS/MS	High Sensitivity, Specificity	Matrix Effects, Recovery	Pharmacokinetic Studies [28]
	UPLC-MS	Rapid Analysis, Low Volume	Extraction Efficiency	Bioequivalence Studies [33]
Pharmaceutical Products	HPLC-UV	Robust, Cost-effective	Method Transfer	Quality Control [10]
	Spectrophotometry	Simple, Rapid	Linear Range	Routine Analysis [12]
Environmental Samples	Green Chromatography	Eco-friendly, Selective	Method Robustness	Environmental Monitoring [21]
Novel Formulations	Advanced Microscopy	High Resolution Imaging	Method Development	Research Applications [20]
Combination Products	Hyphenated Techniques	Multi-component Analysis	Selectivity	Product Development [37]

4.3.2. Risk Assessment

Systematic risk assessment guides method development and validation strategies. Critical quality attributes receive focused attention during development phases. Continuous method monitoring ensures sustained performance throughout the product lifecycle [35].

4.4. Analysis of Novel Formulation

Emerging delivery technologies necessitate specialized analytical approaches. Smart delivery systems incorporating sensors require integrated analytical solutions. Bioresponsive formulations demand dynamic analytical methods capable of monitoring environmental responses [36]. Analysis of fixed-dose combinations presents unique analytical challenges. Simultaneous determination methods require enhanced selectivity and range. Matrix effects and potential interactions necessitate comprehensive validation approaches [37].

5. Conclusion

The analytical methods for quantification of budesonide continues to evolve, driven by technological advances and sophisticated equipment. UV spectrophotometric methods maintain their significance in routine analysis, offering simplicity and cost-effectiveness. Chromatographic techniques provide enhanced selectivity and sensitivity, particularly valuable for complex formulations and stability studies. Method validation ensures reliable analytical performance, supporting quality control and research applications. Emerging trends point toward increased automation, enhanced detection capabilities, and integration of quality by design principles. Novel delivery systems present analytical challenges, driving innovation in method development. Green analytical chemistry methods influence future method development strategies, promoting environmental sustainability while maintaining analytical performance. The successful implementation of analytical methods for budesonide determination requires careful consideration of multiple factors, including regulatory requirements, operational efficiency, and environmental impact.

References

[1] Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis. 2018;148(4):S1-26.

[2] Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet. 2004;43(12):803-21.

[3] Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042-50.

[4] Sjöberg M, Sandström P, Sjödin L. Pharmacokinetics and absorption of budesonide in patients with Crohn's disease and healthy volunteers. Aliment Pharmacol Ther. 2016;44(5):495-507.

[5] Hochhaus G, Möllmann H. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 2015;30(9):342-62.

[6] Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372-80.

[7] Traynor K, Rubin BK. Assessing the performance of inhaler devices in delivering aerosolized medications. Expert Rev Med Devices. 2019;16(1):73-83.

[8] Rodríguez-Roldán M, González-Alvarez I, Bermejo M. A review on the dissolution testing of budesonide formulations. Int J Pharm. 2020;580:119182.

[9] Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics. FDA. 2015.

[10] Zhang L, Chawla A, Zhou M. Development and validation of a stability-indicating HPLC method for simultaneous determination of budesonide and formoterol fumarate in metered dose inhaler. J Pharm Biomed Anal. 2017;146:189-196.

[11] ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R1). International Conference on Harmonisation. 2005.

[12] Gupta V, Jain AD, Gill NS, Gupta K. Development and validation of HPLC method - a review. Int Res J Pharm App Sci. 2012;2(4):17-25.

[13] Srikanth K, Nalluri BN. Development and validation of a HPLC-UV method for the simultaneous determination of budesonide and formoterol in pharmaceutical dosage forms. Int J Pharm Sci Res. 2016;7(11):4436-43.

[14] Ermer J, Miller JH. Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. 2nd ed. Wiley-VCH; 2015.

[15] Görög S. Advances in the analysis of steroid hormone drugs in pharmaceuticals and environmental samples. J Pharm Biomed Anal. 2011;55(4):728-43.

[16] Nováková L, Douša M. Modern HPLC separation of pharmaceuticals including potential impurities, metabolites and degradation products. J Pharm Biomed Anal. 2017;147:378-392.

[17] Radhakrishna T, Narasaraju A, Ramakrishna M, Satyanarayana A. Contemporary LC-MS methods for the determination of budesonide and related compounds in pharmaceutical preparations. J Pharm Biomed Anal. 2016;131:459-472.

[18] Shinde VM, Desai BS, Tendolkar NM. Stability-indicating HPLC determination of budesonide in pharmaceutical formulations. J Chromatogr Sci. 2010;48(1):35-41.

[19] Mukhopadhyay S, Basu K, Das S. Forced degradation studies and HPLC-UV method development for simultaneous estimation of formoterol fumarate and budesonide in dry powder inhaler formulation. Drug Dev Ind Pharm. 2020;46(1):155-169.

[20] Ali ME, Lamprecht A. Spray freeze drying for dry powder inhalation of nanoparticles. Eur J Pharm Biopharm. 2014;87(3):510-517.

[21] Plotka-Wasylka J, Szczepanska N, de la Guardia M, Namiesnik J. Modern trends in solid phase extraction: New sorbent media. TrAC Trends Anal Chem. 2016;77:23-43.

[22] Rozet E, Marini RD, Ziemons E, Boulanger B, Hubert P. Advances in validation, risk and uncertainty assessment of bioanalytical methods. J Pharm Biomed Anal. 2011;55(4):848-858.

[23] Tiwari G, Tiwari R. Bioanalytical method validation: An updated review. Pharm Methods. 2010;1(1):25-38.

[24] Validation of Chromatographic Methods. Center for Drug Evaluation and Research (CDER), FDA. 2014.

[25] De Spiegeleer B, Baert B, Vergote V, Van Dorpe S. Development of system suitability tests for in-process control of pharmaceutical analysis. J Chromatogr A. 2008;1189(1-2):266-277.

[26] Bajaj S, Singla D, Sakhuja N. Stability testing of pharmaceutical products. J Appl Pharm Sci. 2012;2(3):129-138.

[27] Swartz M, Krull I. Analytical Method Development and Validation. Marcel Dekker; 2012.

[28] Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75(13):3019-3030.

[29] Pandya RB, Mehta PJ, Patel PU. Development and validation of stability indicating UV spectrophotometric method for estimation of budesonide in pharmaceutical dosage forms. Int J Drug Dev Res. 2015;7:11-17.

[30] Ermer J, Nethercote P. Method validation in pharmaceutical analysis: A guide to best practice. 2nd ed. Wiley-VCH; 2015.

[31] World Health Organization. WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing. WHO Technical Report Series. 2011;961:285-309.

[32] Patel DS, Sharma N, Patel MC, Patel BN, Shrivastav PS, Sanyal M. Development and validation of a selective and sensitive LC-MS/MS method for determination of cyclophosphamide in human plasma. J Chromatogr B. 2017;1040:297-304.

[33] May JC, Goodwin CR, McLean JA. Ion mobility-mass spectrometry strategies for untargeted system-wide analysis of metabolomes. Curr Opin Biotechnol. 2015;31:117-121.

[34] Monks K, Molnár I, Rieger HJ, Bogáti B, Szabó E. Quality by Design: Multidimensional exploration of the design space in high performance liquid chromatography method development for better robustness before validation. J Chromatogr A. 2012;1232:218-230.

[35] Borman P, Elder D. Q2(R1) Validation of Analytical Procedures. In: ICH Quality Guidelines: An Implementation Guide. 2017:127-166.

[36] Colombo P, Traini D, Buttini F. Inhalation Drug Delivery: Techniques and Products. Wiley-Blackwell; 2013.

[37] García-Arieta A. Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: Impact on bioequivalence. Eur J Pharm Sci. 2014;65:89-97.

Author's short biography

Mrs. Bhavya KB

Mrs. Bhavya KB, a dedicated professional with an M. Pharm degree who presently works as an Assistant Professor in the Department of Pharmaceutical Analysis at Bharathi College of Pharmacy in Bharathi Nagar, Karnataka. She is passionate about pharmaceutical education and helps shape the destinies of young pharmacists. The position entails providing theoretical and practical insights while promoting a dynamic learning environment. Her dedication to continual learning and research has a huge influence, making them a respected member of the faculty at Bharathi College.

Mr. Chethana KS

Mr. Chethana KS is currently pursuing his Bachelor of Pharmacy degree with distinction. He has exceptional aptitude in pharmaceutical sciences and consistently prepares himself to master both theoretical concepts and practical applications within the discipline.

Miss Divya Shree MP

Miss Divya Shree MP is an ambitious Bachelor of Pharmacy student specializing in pharmaceutical analysis and method development. Her academic journey reflects a particular affinity for analytical techniques and their applications in ensuring pharmaceutical quality and efficacy.

Mr. Sachin V

Mr. Sachin V shows dedication in his Bachelor of Pharmacy studies. His academic portfolio shows particular strength in pharmaceutical sciences, where his methodical approach and intellectual curiosity have established him as a promising student in the field